Careful, reps: Doctors are watching, FDA promo police's latest rebuke shows

FDA
The FDA's ad cops pushed back on an Eisai drug rep's misleading claims, sending an untitled letter and request to cease. (FDA)

The latest admonishment from the FDA's promo police is an unusual one. In it, the agency scolds an Eisai sales rep accused of misleading healthcare professionals during a presentation on antiseizure drug Fycompa.

What's different about the FDA's latest untitled letter? It involves words spoken by a sales rep. It marks only the 14th time a warning or untitled letter has involved an oral statement, said Mark Senak, a public relations professional and Eye on FDA blogger. The last time a sales rep was involved was in 2012, according to his database of 329 letters dating back to 2004.

RELATED: Ascend scolded—again—for estrogen drug promos in OPDP's 4th warning this year

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Exactly what the Eisai sales rep said is unclear, as much of the explanation of the offense is redacted in the letter. But the letter did note that the tip came from the FDA’s Bad Ad program and in this case seems clearly to be from someone who was in the room during the Eisai rep’s presentation.

Senak noted that this letter and another recent letter both came through the Bad Ad program, which encourages healthcare professionals to report instances of misleading drug promotion with a direct phone call or email to the Office of Prescription Drug Promotion (OPDP).

“For anyone who thought Bad Ads was a dormant program, it apparently is not,” Senak said via email. “The message to sales reps is that docs are listening and docs are reporting and when they do, the FDA may act.”

RELATED: Pfizer chastised for missing risks in pharma ad police's second letter of 2018

When asked if the sales rep letter might have a chilling effect on rep speech, Senak said he doesn’t think so. He noted that reps already go through training about communications boundaries and the letter doesn’t send any new messages in that regard.

The Eisai letter brings the total of OPDP enforcement letters for 2018 up to six, a tally that's pulled ahead of 2017’s total of five letters. Letters have been on the decline over the past several years, although the agency sent 11 in 2016 and nine in 2015.

Still, Senak thinks those in healthcare communications should "sit up and take note" after the latest letter, he wrote in a recent column

"While OPDP has been less active on the enforcement front, the letters this week demonstrate that when the agency receives complaints via the Bad Ad program, it will act on them, particularly where … it believes there is a safety issue—which may be more pronounced when a product has a boxed warning,” he said.

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.